---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-027585"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:08:31.528152+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbbVie issues $15B in senior notes across 7 tranches to fund acquisitions and repay debt

## Summary
- Issued $15.0B aggregate principal of senior notes maturing 2027-2064 with coupons from 4.800% to 5.500%.
- Proceeds will prepay $5.0B term loan used for ImmunoGen acquisition and fund pending Cerevel acquisition.
- Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured indebtedness.
- Underwriters include Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup.

## SEC filing metadata
- accession: 0001104659-24-027585
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465924027585/0001104659-24-027585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465924027585/tm246405d5_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-027585
- JSON: https://secwatch.observer/filing/0001104659-24-027585.json
- Plain text: https://secwatch.observer/filing/0001104659-24-027585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.